focus -WSS

focus

author：Wikipedia 2025-08-25 07:29:26 - browse：6325

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： STAT Virtual Event: Putting AI to the Test

WSS

Cholera vaccine supplies dangerously low, outbreaks surging

Virtual repurposing can help discover new uses for existing drugs

Change Healthcare cyberattack shows risk of industry consolidation

CDC advisory group OKs chikungunya vaccine

Are embryos people? Reproductive medicine's future depends on the answer

Change Healthcare cyberattack shows risk of industry consolidation

focus

focus

focus

Jerome Adams on the need for new antivirals for Covid

What Congress can do to address the rural doctor shortage

Heart attack and stroke risk calculators need revising

5 ways to address the shortage of health care workers

After affirmative action ruling, medical educators look to 'holistic review'

Cholera vaccine supplies dangerously low, outbreaks surging

Affirmative action in medical school literally saved lives

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Wildfire smoke exposes gaps in outdoor worker protections

Changes to biosimilar regulatory framework must prioritize patients

hotspot

Second xenotransplant done with gene

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

What Congress can do to address the rural doctor shortage

Doctor of U.S. President Joe Biden says he is fit for duty

Medical student insurance fails on mental health care coverage

How Vertex's cystic fibrosis drug is changing patients' lives

Wikipedia

hotspot

knowledge

focus